Business Wire09.11.20
Bruker Corporation has acquired Canopy Biosciences LLC, a company specializing in high multiplex biomarker imaging for immunology, immuno-oncology and cell therapy.
This acquisition enhances Bruker’s offering in targeted multi-omics and fluorescence-based imaging techniques. Bruker’s global reach, complementary technologies and applications knowledge will help build on Canopy’s success to date.
“We are excited to add the multi-omics and high-content cytometry expertise of Canopy, and its novel ChipCytometry platform to Bruker,” said Dr. Mark R. Munch, the Bruker NANO group president. “Canopy has a unique set of products that enable single cell, tissue and suspended cell-based discovery and validation in immunology and targeted proteomics, as well as a suite of complementary multi-omics services.”
“We are very pleased to join Bruker,” added Dr. Edward Weinstein, the CEO of Canopy Biosciences. “Joining forces with a leading life-science tools provider with broad geographic reach enables us to give many more researchers access to our powerful high-plex ChipCytometry platform, designed for accelerating basic immunology and clinical research, as well as biopharma drug development.”
“Canopy has built a powerful suite of multi-omics technologies,” explained Dr. Frank Witney, operating partner of Ampersand Capital Partners, the lead Canopy investor. “Joining Bruker will strengthen and deepen this platform, enabling researchers to better answer their scientific and translational questions with unprecedented power and precision.”
Financial details of the transaction were not disclosed.
This acquisition enhances Bruker’s offering in targeted multi-omics and fluorescence-based imaging techniques. Bruker’s global reach, complementary technologies and applications knowledge will help build on Canopy’s success to date.
“We are excited to add the multi-omics and high-content cytometry expertise of Canopy, and its novel ChipCytometry platform to Bruker,” said Dr. Mark R. Munch, the Bruker NANO group president. “Canopy has a unique set of products that enable single cell, tissue and suspended cell-based discovery and validation in immunology and targeted proteomics, as well as a suite of complementary multi-omics services.”
“We are very pleased to join Bruker,” added Dr. Edward Weinstein, the CEO of Canopy Biosciences. “Joining forces with a leading life-science tools provider with broad geographic reach enables us to give many more researchers access to our powerful high-plex ChipCytometry platform, designed for accelerating basic immunology and clinical research, as well as biopharma drug development.”
“Canopy has built a powerful suite of multi-omics technologies,” explained Dr. Frank Witney, operating partner of Ampersand Capital Partners, the lead Canopy investor. “Joining Bruker will strengthen and deepen this platform, enabling researchers to better answer their scientific and translational questions with unprecedented power and precision.”
Financial details of the transaction were not disclosed.
